0:00
A new weight loss pill that targets hormones in the same way popular weight loss injections do
0:04
is showing promise in late stage trials. Drug maker Eli Lilly says its GLP-1 pill called Orphaglipron met its goals in the first of seven
0:15
phase three trials. The first trial was specific to people with type 2 diabetes
0:20
Eli Lilly says the pill not only helped diabetics lower their blood sugar
0:24
it also helped them lose weight. On average, those taking the pill at the highest dose
0:29
lost about 8% of their body weight, or around 16 pounds, which could be a real game changer for those living with type 2 diabetes or prediabetes
0:38
Eli Lilly also said so far the pill is just as safe as any of the popular weight loss injections on the market
0:45
Orfor glipron works similarly to terzepatide, the ingredient in Manjaro, Eli Lilly's injection to treat type 2 diabetes
0:54
Terzepatide is also what's used in the company's injectable, specifically by the FDA for weight loss set bound
1:01
But unlike the injections, the pill is taken daily instead of weekly. While terzepatide targets two weight-related hormones
1:08
Orfolglipron only targets one. However, there was only a slight difference in total weight loss between the two
1:15
The side effects were also similar, mainly gastrointestinal issues. The success of Eli Lilly's pill comes just days after rival drug maker Pfizer said
1:25
it would stop testing its own weight loss pill after a patient experienced liver issues
1:31
To keep up to date with all the health issues, download the Straight Arrow News app or go to san.com
